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Electrospray ionisation mass spectrometry has been used to show that the synthetic 40 ammo acid /7-amyloid peptide @140) interacts with the 
cyclic oligosaccharide/?-cyclodextrin. This interaction, presumably with the hydrophobic aromatic moieties on the peptide, has been shown to diminish 
substantially the neurotoxic effects of /340 in a cell line. 
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1. Introduction 
Alzheimer’s disease is characterised pathologically by 
the classical senile plaque in the human brain. This con- 
sists of a central core surrounded by dystrophic neurites, 
reactive microglia and astrocytes. The major constituent 
of the plaque core has been shown [1,2] to be the /3-A4 
amyloid peptide, containing 3943 amino acids (Fig. 1). 
The function of /I-amyloid is poorly understood. It has 
been shown, as least in vitro, to possess both neurotoxic 
and neurotrophic properties, and it may also function as 
an adhesion molecule [3]. Studies in vitro have reported 
neurotoxicity in cultured neuronal preparations [4,5] and 
in cell lines [6]. Early controversy regarding whether /I- 
amyloid was neurotoxic in vitro appear to have been 
resolved by ‘ageing’ studies. After 24 days preincuba- 
tion, /?-A4 fibrillises and is neurotoxic to rat hippocam- 
pal neurones, whilst in its freshly solubilised state the 
material is lacking in toxicity and may even promote 
neurite outgrowth [4]. The adoption of a B-sheet confor- 
mation is thought [7] to be essential for aggregation and 
fibrillisation of /I-A4. It has also been suggested that it 
is the interaction between the hydrophobic residues of 
/I-A4 that is the primary mechanism of the aggregation 
process [7]. Reduction in the interaction of the residues 
could ultimately be an important factor in controlling the 
progression of Alzheimer’s disease. 
We have shown recently [8] that peptides containing 
aromatic acid residues, in particular tryptophan and 
phenylalanine, interact with /?-cyclodextrin. Encapsula- 
tion of such residues by this water-soluble oligosac- 
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charide can alter both the secondary structure of pep- 
tides and their hydrophobicity characteristics. 
It is well known [9] that the B-chain of insulin is in- 
volved in the formation of dimers and higher polymers. 
This chain contains three phenylalanine and two tyrosine 
residues in comparison to the A-chain which only con- 
tains two tyrosine residues. It is of interest hat the addi- 
tion of hydroxypropyl-/Lcyclodextrin has been reported 
[lo] to prevent the aggregation of insulin in solution at 
ambient temperatures. Such an inhibition may well be 
due to conformational changes in the insulin as a result 
of complexation with the cyclic oligosaccharide. 
In the present study, we examine the ability of the 40 
amino acid /%amyloid protein Ggl.40) to interact with 
/I-cyclodextrin and we investigate if this interaction can 
control the neurotoxic effects of the peptide. 
2. Materials and methods 
2.1. Mass spectroscopy studies 
A solution (100~1) ofp1-40 in water:methanol, I:1 (v/v), containing 
5% acetic acid (v/v) (0.5 mg/ml) was added to a solution (100 ~1) of 
@yclodextrin in water (0.16 mM, about 0.185 g/l). An aliquot of this 
mixture (50 ~1) was injected into a flow of water:methanol, 1:l (v/v) (4 
@/mm), and transported to an electrospray source fitted to a single 
stage quadrupole mass spectrometer (Vestec 201-A; Vestec Corp., 
Houston, TX). Ionisation was affected by applying 2.5 kV to the elec- 
trospray needle; spectra were recorded over a mass range of 2000 to 
100 u with 20 s scans in profile mode. 
2.2. Fibrillisation of /3140 and neurotoxicity assay 
The /?140 used in the present experiments was Lot No. ZK600 
purchased from Bachem UK Ltd. The peptide was initially dissolved 
in 0.1% acetic acid at 4.6 mM (2 mg/ml). Greater than 95% fibrillisation 
was induced by diluting with peptide solution with 4 ~01s. of 62.5 mM 
MES buffer, pH 5.75, and incubating at room temperature for 2 h 
(Wetzel, Wood, personal communication). 
Where tested, p-cyclodextrin was present in the MES buffer at 15 
mM. Following this fibrillisation step, the samples were diluted to 
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Fig. 1. Amino acid sequence of /?-A4 peptide. 
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appropriate concentrations for the neurotoxicity assay in Dulbecco’s 
Minimal Essential Medium (DMEM). 
To assess neurotoxicity, PC12 &lls (rat phaeochromocytoma; 
ECACC. Porton Down. UK) were olated at 6 x 104 cells/cm2 in a 
96-well kcrotitre plate &uni). Afte; 2 h attachment, fresh DMEM 
containingp1-40, jkyclodextrin or both, was then added. The highest 
concentra%on of BldO used was 23 ,uM (= 10 ,ug/ml): this contaked, 
due to the dilution. 75 uM B-cvclodextrin. After a further 24 h. cell 
viability was asked by ah klT assay, which depends upod the 
integrity of mitochondrial respiration for the conversion of the meta- 
bolic dye MTT to a blue formazan product. 
The degree of fibrillisation was estimated by incubating the /llAO 
solution, in the presence or absence of j?-cyclodextrin, with 25 PM 
Congo red solution, pH 7.4, and calculating the amount of Congo red 
bound [l 11. 
3. Results and discussion 
The electrospray mass spectrum of synthetic Bl-40 is 
shown in Fig. 2a. The two signals at values of m/2 of 
1444.3 and 1083.5 correspond to the [M + 3H13+ and 
[M + 4H14+ forms of the peptide, respectively, and are 
consistent with a molecular weight of 4330. The spec- 
trum reported [ 121 for the 42 amino acid peptide (dis- 
solved in 0.1% trifluoroacetic acid in water) consists of 
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two peaks corresponding to the [A + 4H14+ and 
[A + 5HlS+ ions of this peptide. The difference in ionisa- 
tion between the two peptides is probably due to the 
strength of the trifluoroacetic acid (used by the authors 
of [12]) which will generate more protonation and also 
destroy the conformation of the peptide. In the presence 
of j&cyclodextrin, B1-40 shows a number of additional 
peaks (Fig. 2b) related to complexation between the two 
molecules. The strongest signal at m/2 1367 corresponds 
to a 1:l complex, [A + CD + 4H14*. In addition, a 
smaller peak related to the tri-ionised form 
[A + CD + 3H13’ is observed. Higher complexes of the 
forms [A + 2CD + 4H14+ and [A + 3CD + 4H14+ at m/2 
165 1 and 1834 are also seen. It is interesting that a penta- 
ionised species [A + 3CD + 5H]‘+ at m/2 1549 appears to 
be stabilised in the presence of the oligosaccharide. 
/U--40 contains one tyrosine and three phenylalanine 
residues so that the main peptide-cyclodextrin com- 
plexes observed are almost entirely due to inclusion com- 
plexation of the hydrophobic aromatic moieties and the 
hydrophobic cavity of the cyclic oligosaccharide. Re- 
cently, we reported [8] the use of electrospray mass spec- 
b) 
loo_ 
90 - 
80 - 
,651 
IA+2CD+IHI~+ ,822 
10 
0 u 
1000 1500 2000 
Fig. 2. Electrospray mass spectrum of synthetic /?140 in (a) the absence and (b) the presence of p-cyclodextrin. 
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In the absence of jkyclodextrin, B1-40 which had 
been incubated firstly in MES buffer and subsequently 
with Congo red solution, bound 2.3 ,uM Congo red. 
When /3_cyclodextrin (15 mM) was included in the MES 
buffer, only 0.1 ,uM of Congo red was subsequently 
bound. Although high concentrations of /kcyclodextrin 
do inhibit directly the binding of Congo red to fibrils, the 
effects observed in these present experiments are due to 
a prevention of fibril formation since the inclusion of an 
appropriate dilution of /Lcyclodextrin in the Congo red 
solution after fibril formation only had a small effect on 
the Congo red binding (1.6 ,uM bound). 
These data support the suggestion that /3-cyclodextrin 
does indeed interact with /G-40. Moreover, it appears 
that as a result of such an interaction, a considerable 
reduction in the neurotoxic effects of the peptide are 
observed. It can be inferred, from these results, that an 
inhibition of the fibrillisation ofj?l-40 attenuates its neu- 
rotoxic effects. 
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Fig. 3. Effects ofp-cyclodextrin on neurotoxicity top14 in PC12 cells. 
(a) 3 x lo4 cells/cm2 and (b) 6 x lo4 cells/cm’. 
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trometry to monitor the formation of such complexes for 
a number of peptides. We have now also found that 
minor signals could be the result of interactions between 
basic residues and the hydrophobic outer surface of the 
/3-cyclodextrin. Such interaction can give rise to the for- 
mation of higher complexes. Having obtained mass spec- 
trometric values for the interaction of cyclodextrin with 
pl-40, we investigated whether such an interaction could 
reduce or prevent the neurotoxic effects of this peptide. 
Samples of Bl-40 were allowed to fibrillise in the pres- 
ence and absence of jkyclodextrin, as described in sec- 
tion 2. The results, at two different cell densities, are 
shown in Fig. 3. In the absence of jIl-40, j?-cyclodextrin 
had no effect on cell viability (data not shown). The 
presence of j&cyclodextrin during the fibrillisation time 
substantially reduced the cell loss induced by 0.23- 
23 PM /%40. 
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